Intranasal sodium hyaluronate on the nasal cytology of patients with allergic and nonallergic rhinitis

Gelardi, Matteo; Iannuzzi, Lucia; Quaranta, Nicola

doi:10.1002/alr.21193

Cited by 36 publications

(50 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HYA is an active component of two inhalation products. Yabro ® (Ibsa Farmaceutici, IT) is a high viscosity hyaluronate solution for nebulization (MW 800-1000 kDa, 0.3% w/v) to reduce bronchial reactivity induced by inhalation of allergens/pollutants or by physical effort (Gelardi et al, 2013). In this formulation, HYA improves palatability and reduces potential side effects of nebuliser solutions such as irritation and cough.…”

Section: Introductionmentioning

confidence: 99%

Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery

Martinelli

Balducci

Kumar

et al. 2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery.International Journal of Pharmaceutics http://dx.doi.org/10. 1016/j.ijpharm.2016.12.002 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Abstract:Sodium hyaluronate (HYA) warrants attention as a material for inhalation due to its (i) therapeutic potential, (ii) utility as a formulation excipient or drug carrier, and (iii) ability to target lung inflammation and cancer. This study aimed to overcome formulation and manufacturing impediments to engineer biocompatible spray-dried HYA powders for inhalation. Novel methodology was developed to produce HYA microparticles by spray drying. Different types of surfactant were included in the formulation to improve powder respirability, which was evaluated in vitro using cascade impactors. The individual formulation components and formulated products were evaluated for their biocompatibility with A549 respiratory epithelial cells. The inclusion of stearyl surfactants, 5% w/v, produced the most respirable HYA-powders; FPF 59.0-66.3%. A trend to marginally higher respirability was observed for powders containing stearylamine > stearyl alcohol > cetostearyl alcohol. Pure HYA was biocompatible with A549 cells at all concentrations measured, but the biocompatibility of the stearyl surfactants (based on lethal concentration 50%; LC50) in the MTT assay ranked stearyl alcohol > cetostearyl alcohol > stearylamine with LC50 of 24.7, 13.2 and 1.8 µg/mL, respectively. We report the first respirable HYA powders produced by spray-drying. A lead formulation containing 5% stearyl alcohol was identified for further studies aimed at translating the proposed benefits of inhaled HYA into safe and clinically effective HYA products.

show abstract

Section: Introductionmentioning

confidence: 99%

Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery

Martinelli

Balducci

Kumar

et al. 2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Samples were placed on a glass slide, fixed by air drying and stained according to the May-Grunwald Giemsa (IR MEDICAL, Lugo, RA, Italy) method and then observed by optical microscope (13). The nasal cytological assessment, performed in blind condition by two investigators who were unaware ofthe assigned treatment, evaluated the presence and the number of neutrophils, eosinophils, mast cells, bacteria and fungi according to a 0-4 score (0 = absent, 1 = rare, 2 = some, 3 = easily visible, 4 = many) (13). Ciliary motility was assessed on fresh samples by contrast-phase microscope according to a 0-3 score (0 = absent, 1 = < 5',2 = 2: 5' and:::: 10',3 = > 10'), where a higher value corresponds to a better motility (14).…”

Section: Methodsmentioning

confidence: 99%

Nasal Cytological Assessment after Crenotherapy in the Treatment of Chronic Rhinosinusitis in the Elderly

Cantone

Ferranti

et al. 2014

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Chronic rhinosinusitis (CRS) determines irreversible alterations of the nasal mucosa with consequent impairment of ciliary movements and, therefore, mucociliary clearance (MCC). People of all ages can be affected by CRS but the elderly are subjects at the highest risk. CRS in the elderly with an age-related physiological impairment of nasal respiratory function, often accompanied by other chronic diseases, requires additional therapies to be added to the numerous daily medications. Since the currently available therapies for CRS include the use of drugs that can have adverse effects and contraindications, crenotherapy could represent a therapeutic option. Indeed, because the adverse effects and contraindications of crenotherapy are scarce, it can be safely used in elderly patients with comorbidities. The aim of this study is to evaluate the nasal cytological assessment after crenotherapy in elderly subjects with CRS. Two groups, comprising a total of 84 elderly subjects with CRS, were treated with crenotherapy with sodium chloride sulphate hyperthermal water rich in mineral salts (group I, n=49) and saline solution (group II n=35). Cytological assessment for both groups took place at baseline (T0) and 1 month after treatment (T30). At T30 the nasal cytological assessment showed statistically significant improvements in the ciliary motility and in the count of neutrophils and spores in group I, but not in group II. Conversely, there were no significant differences in the count of eosinophils, mast cells, bacteria and biofilm in either group. Our data for the first time focused on the role of crenotherapy in the improvement of cytological assessment of CRS in the elderly.

show abstract

“…Hence, exogenous HMW HA represents a promising therapeutic agent for the treatment of nasal and lung diseases that involve inflammation, oxidative stress and epithelial remodeling, such as allergic and non-allergic rhinitis, asthma, chronic obstructive pulmonary disease and cystic fibrosis [143,233,[235][236][237][238]. Examples of marketed formulations containing HA to treat respiratory diseases are Ialoclean® (Farma-Derma) a nasal spray to treat nasal dryness and rhinitis, and to promote nasal wound healing-, Hyaneb® (Chiesi Farmaceutici) -a hypertonic saline …”

Section: Rhinology and Pneumologymentioning

confidence: 99%

“…On the other hand, crosslinking is normally intended to improve the mechanical, rheological and swelling properties of HA, and reduce its degradation rate, in order to develop derivatives with a longer residence time in the site of application and greater release properties [58,138,139]. A recent trend is to conjugate and crosslink HA chains using bioactive molecules in order to develop derivatives with improved and customized activities [58] for a variety of applications in medicine, aesthetic and bioengineering -including cell and molecule delivery, tissue engineering, and development of scaffolds [46,56,58,[140][141][142][143][144]. A number of synthetic approaches have been developed to produce conjugated or crosslinked hyaluronan [136].…”

Section: General Introduction On the Chemical Approaches To Modify Hamentioning

confidence: 99%

Hyaluronic Acid in the 3<sup>rd</sup> Millennium

Fallacara¹,

Baldini²,

Manfredini³

et al. 2018

Preprint

View full text Add to dashboard Cite

Since its first isolation in 1934, hyaluronic acid (HA) has been studied across a variety of research areas. This unbranched glycosaminoglycan consisting of repeating disaccharide units of N-acetyl-D-glucosamine and D-glucuronic acid is almost ubiquitary in humans and in other vertebrates. HA is involved in many key processes -including cell signaling, wound reparation, tissue regeneration, morphogenesis, matrix organization and pathobiology-, and has unique physico-chemical properties -such as biocompatibility, biodegradability, mucoadhesivity, hygroscopicity and viscoelasticity. For these reasons, exogenous HA has been investigated as drug delivery system and treatment in cancer, ophthalmology, arthrology, pneumology, rhinology, urology, aesthetic medicine and cosmetic. To improve and customize its properties and applications, HA can be subjected to chemical modifications: conjugation and crosslinking. The present review gives an overview regarding HA, describing its history, physico-chemical, structural and hydrodynamic properties, and biology -occurrence, biosynthesis (by hyaluronan synthases), degradation (by hyaluronidases and oxidative stress), roles, mechanisms of action and receptors. Furthermore, both conventional and recently emerging methods developed for the industrial production of HA and its chemical derivatization are presented. Finally, the medical, pharmaceutical and cosmetic applications of HA and its derivatives are reviewed, reporting examples of HA-based products which currently are on the market or are undergoing further investigations.

show abstract

Intranasal sodium hyaluronate on the nasal cytology of patients with allergic and nonallergic rhinitis

Cited by 36 publications

References 44 publications

Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery

Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery

Nasal Cytological Assessment after Crenotherapy in the Treatment of Chronic Rhinosinusitis in the Elderly

Hyaluronic Acid in the 3<sup>rd</sup> Millennium

Contact Info

Product

Resources

About